HSV helicase-primase inhibitors (Boehringer Ingelheim)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameHSV helicase-primase inhibitors (Boehringer Ingelheim)
Drug Alias NameBILS-22-BSBILS-179-BS
ClassificationSmall molecules
Mechanisms of ActionDNA primase inhibitorsRNA helicases inhibitorsHSV replication inhibitors
TargetsRNA helicasesDNA primase
Therapy Area/IndicationsHerpes Simplex
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim (Canada) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsHerpes Simplex

Other Information

ATC CodeN/A
Related LinksN/A